- Home
- KPLT vs AKTX Comparison
KPLT vs AKTX Comparison
Compare KPLT & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPLT
- AKTX
- Stock Information
- Founded
- KPLT 2012
- AKTX N/A
- Country
- KPLT United States
- AKTX United States
- Employees
- KPLT N/A
- AKTX N/A
- Industry
- KPLT Diversified Commercial Services
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- KPLT Consumer Discretionary
- AKTX Health Care
- Exchange
- KPLT Nasdaq
- AKTX Nasdaq
- Market Cap
- KPLT 30.1M
- AKTX 34.7M
- IPO Year
- KPLT N/A
- AKTX N/A
- Fundamental
- Price
- KPLT $8.86
- AKTX $1.26
- Analyst Decision
- KPLT Hold
- AKTX
- Analyst Count
- KPLT 2
- AKTX 0
- Target Price
- KPLT $12.00
- AKTX N/A
- AVG Volume (30 Days)
- KPLT 176.0K
- AKTX 64.3K
- Earning Date
- KPLT 03-13-2025
- AKTX 02-15-2025
- Dividend Yield
- KPLT N/A
- AKTX N/A
- EPS Growth
- KPLT N/A
- AKTX N/A
- EPS
- KPLT N/A
- AKTX N/A
- Revenue
- KPLT $241,789,000.00
- AKTX N/A
- Revenue This Year
- KPLT $12.92
- AKTX N/A
- Revenue Next Year
- KPLT $6.23
- AKTX N/A
- P/E Ratio
- KPLT N/A
- AKTX N/A
- Revenue Growth
- KPLT 14.99
- AKTX N/A
- 52 Week Low
- KPLT $5.08
- AKTX $0.90
- 52 Week High
- KPLT $23.54
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- KPLT 62.11
- AKTX 51.13
- Support Level
- KPLT $6.24
- AKTX $1.13
- Resistance Level
- KPLT $12.14
- AKTX $1.31
- Average True Range (ATR)
- KPLT 1.00
- AKTX 0.12
- MACD
- KPLT 0.33
- AKTX 0.03
- Stochastic Oscillator
- KPLT 44.69
- AKTX 56.52
About KPLT Katapult Holdings Inc.
Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).